Outcome of fifty-five newborns of antiphospholipid antibody-positive mothers treated with calcium heparin during pregnancy
- PMID: 9779312
Outcome of fifty-five newborns of antiphospholipid antibody-positive mothers treated with calcium heparin during pregnancy
Abstract
Objective: The outcome of 55 infants born to 53 antiphospholipid antibody (aPL)-positive mothers treated during pregnancy with calcium heparin is described.
Methods: The clinical state of the children was evaluated immediately after delivery by a clinical examination, and a neonatological check-up was performed no later than 24 hours after birth. Neonates with problems were transferred to the neonatal intensive care unit. After their discharge from hospital the clinical state of the babies was followed by means of interviews with the pediatricians and mothers for a period varying between 1.33 and 5.66 years (mean 2.51 +/- 0.92 SD).
Results: The newborns comprised 30 females and 25 males, including 2 sets of twins, delivered between the 25th and 40th weeks of gestation (mean 36.69 +/- 2.91 SD). They had a mean birth weight of 2.828 g +/- 706.50 SD (range 800-4.000) and a mean Apgar score at 5 minutes of 9.60 +/- 0.68 SD (range 7-10). Soon after delivery, 12 children (21.81%) were admitted to the neonatal intensive care unit for periods varying between 2 and 120 days (mean 30.33 +/- 33.40 SD), after which the clinical course was normal. All of these neonates suffered from complications exclusively due to prematurity. Malformations and signs of thrombosis or other aPL-related disorders were not observed in any of the newborns. During the follow-up, none of the diseases suffered by the 55 children differed from those of the normal pediatric population; in particular, aPL-related manifestations were never observed.
Conclusion: These data indicate the absence of aPL-related problems in the offspring of aPL-positive mothers treated during pregnancy with calcium heparin.
Similar articles
-
A prospective study of fifty-three consecutive calcium heparin treated pregnancies in patients with antiphospholipid antibody-related fetal loss.Clin Exp Rheumatol. 1997 Sep-Oct;15(5):499-505. Clin Exp Rheumatol. 1997. PMID: 9307857 Clinical Trial.
-
[Pregnancy outcome in the woman with antiphospholipid antibodies: a case report].Ginekol Pol. 2000 Jun;71(6):532-5. Ginekol Pol. 2000. PMID: 11002557 Polish.
-
Fluctuations in levels of antiphospholipid antibodies and increased coagulation activation markers in normal and heparin-treated antiphospholipid syndrome pregnancies.Lupus. 2002;11(1):11-20. doi: 10.1191/0961203302lu132oa. Lupus. 2002. PMID: 11898913 Clinical Trial.
-
Antiphospholipid antibody syndrome.Obstet Gynecol Clin North Am. 2014 Mar;41(1):113-32. doi: 10.1016/j.ogc.2013.10.004. Obstet Gynecol Clin North Am. 2014. PMID: 24491987 Review.
-
Management of women with recurrent pregnancy losses and antiphospholipid antibody syndrome.Am J Reprod Immunol. 2013 Jun;69(6):596-607. doi: 10.1111/aji.12114. Epub 2013 Mar 25. Am J Reprod Immunol. 2013. PMID: 23521391 Review.
Cited by
-
Neonatal effects of maternal antiphospholipid syndrome.Curr Rheumatol Rep. 2009 Feb;11(1):70-6. doi: 10.1007/s11926-009-0010-8. Curr Rheumatol Rep. 2009. PMID: 19171114 Review.
-
Update on the management of the pregnant patient with antiphospholipid antibody.Curr Rheumatol Rep. 2001 Jun;3(3):213-21. doi: 10.1007/s11926-001-0021-6. Curr Rheumatol Rep. 2001. PMID: 11352790 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical